Advancing the science of targeted, patient-centric care.
Mabwell Therapeutics is a U.S.-based biotechnology company whose dedicated scientists are committed to improving the lives of people affected by rare and debilitating diseases. Inspired by our deep experience in science and commitment to improving patient care, we are delivering breakthrough discoveries in novel biotherapeutics that target rare diseases at the molecular level.
Deep knowledge and a devotion to improving the lives of patients.
There are millions of people suffering from rare diseases, and nearly half are children. Yet, over 95% of rare diseases still have no approved treatment.1 At Mabwell Therapeutics, we’re working to change that by turning deep scientific insight into targeted, effective therapies, bringing new hope to people living with rare and debilitating conditions.
MyoDock™, our proprietary muscle-targeted delivery platform, brings molecular therapeutics directly to the site of diseased muscle, improving both efficacy and safety. Where conventional systemic therapies often struggle to achieve efficacy without introducing dose-limiting toxicity, MyoDock significantly enhances the therapeutic index for treatments targeting neuromuscular diseases.
A broad portfolio of drugs that address unmet needs.
We are developing a diverse portfolio of antibody-based therapeutics to help address significant unmet needs in treating rare and debilitating diseases. Our pipeline spans multiple therapeutic areas, including hematology, autoimmune disorders, neurodegenerative conditions, and neuromuscular diseases.
For neuromuscular indications, we leverage our proprietary MyoDock™ technology to enable precise, dynamic delivery of therapeutics directly to the site of disease. This versatile delivery platform can be used with a wide range of payloads, ensuring direct intervention at the molecular source of disease.
We are always looking for talent. Join us!
We’re on the move and looking for dedicated, innovative scientists to power our ascent. Together, we can develop novel therapeutics to help patients struggling to live with rare and debilitating diseases. Learn more about open positions and what it’s like working here.
1Shan Z, Ding L, Zhu C, Sun R, Hong W. Medical care of rare and undiagnosed diseases: Prospects and challenges. Fundam Res. 2022 Sep 7;2(6):851-858. doi: 10.1016/j.fmre.2022.08.018. PMID: 38933390; PMCID: PMC11197738.